China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 52,570 shares, a drop of 29.1% from the February 12th total of 74,183 shares. Based on an average trading volume of 72,335
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1.68 | $2.57 | $0.89 | 52.98% |
| Specialty Retail Industry | Consumer Discretionary Sector | Feng Zhou CEO | NASDAQ (CM) Exchange | G2161P165 CUSIP |
| CN Country | 75 Employees | - Last Dividend | 3 Feb 2026 Last Split | 4 Jan 2019 IPO Date |
China SXT Pharmaceuticals, Inc. is a distinguished pharmaceutical company deeply rooted in the research, development, manufacturing, and marketing of traditional Chinese medicine pieces (TCMP) within China. Since its inception in 2005, the company has committed itself to preserving the rich heritage of Chinese medicine while incorporating modern scientific methods to enhance the efficacy and reliability of its products. Based in Taizhou, China, China SXT Pharmaceuticals has successfully established a wide network that spans across 10 provinces and municipalities in China, which includes prestigious pharmaceutical companies, chain pharmacies, and hospitals. Through its dedication to quality and innovation, the company has carved a niche for itself in the market, offering an array of TCMP products under the respected brand names Suxuantang, Hui Chun Tang, and Tong Ren Tang.